We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Atreca Inc (BCEL) NPV A

Sell:$0.085 Buy:$0.085 Change: $0.0051 (5.66%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:$0.085
Buy:$0.085
Change: $0.0051 (5.66%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:$0.085
Buy:$0.085
Change: $0.0051 (5.66%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

Contact details

Address:
835 Industrial Road
, 75 SHOREWAY ROAD, SUITE C
SAN CARLOS
94070
United States
Telephone:
+1 (650) 5952595
Website:
https://www.atreca.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCEL
ISIN:
US04965G1094
Market cap:
$3.57 million
Shares in issue:
45.15 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Orwin
    President, Chief Executive Officer, Principal Financial Officer, Director
  • Tito Serafini
    Co-Founder, Director
  • Rick Ruiz
    Principal Accounting Officer
  • Courtney Phillips
    General Counsel, Corporate Secretary
  • Philippe Bishop
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.